CYP3A4 and musculoskeletal system disorder: On the other hand, the prevalence of oral analgesic use, in CYP3A4 (42.8%) and NO-CYP3A4 (42.1%), was similar to that previously reported in individuals with musculoskeletal disorders with lipid-lowering drug use (41.0%) [26].